ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP) from its SEC filings: 2025 revenue $883.4 million (+44% vs the year before), net margin 9%, free cash flow $171.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $883.4 million |
| Revenue growth | +44% |
| Net income | $78.0 million |
| Net margin | 8.8% |
| Free cash flow | $171.4 million |
| Diluted EPS | $3.32 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +26% |
| Cash | $360.2 million |
| Long-term debt | $280.2 million |
| Share count, 1 year | -80% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.